Podcast appearances and mentions of James M Foran

  • 13PODCASTS
  • 29EPISODES
  • 54mAVG DURATION
  • ?INFREQUENT EPISODES
  • Sep 17, 2024LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about James M Foran

Latest podcast episodes about James M Foran

Targeted Talks
S5 Ep16: Foran Goes Beyond the Basics of BPDCN

Targeted Talks

Play Episode Listen Later Sep 17, 2024 22:32


In this episode of Targeted Talks, James M. Foran, MD, discusses the presentation and diagnosis of blastic plasmacytoid dendritic cell neoplasm. 

md basics foran james m foran
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
James M. Foran, MD, FRCPC, Jessica K. Altman, MD - The Convergence of Innovative Therapy and AlloHCT in AML: Applying Current Evidence to Improve Outcomes

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 28, 2023 58:11


Go online to PeerView.com/KZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how to apply the evidence that supports modern therapeutics in conjunction with allogeneic hematopoietic stem cell (HCT)! This "Clinical Consults" activity features an expert-led, case-centered discussion focusing on therapeutic decision-making in HCT-eligible acute myeloid leukemia (AML). Throughout, the panelists weigh in on topics such as how to incorporate targeted options into the management of HCT-eligible patients based on FLT3 or TP53 mutations, selection of appropriate postremission maintenance, and the use of novel conditioning to expand access to HCT for AML populations with unmet medical needs. Upon completion of this activity, participants should be better able to: Characterize baseline disease- and patient-related features that can inform prognosis and facilitate treatment decisions for transplant-eligible patients with AML; Integrate novel therapies into induction, consolidation, and maintenance/postremission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines; and Incorporate novel therapies into treatment plans for patients with relapsed/refractory AML, including as pretransplant conditioning or as salvage options post-transplant

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
James M. Foran, MD, FRCPC, Jessica K. Altman, MD - The Convergence of Innovative Therapy and AlloHCT in AML: Applying Current Evidence to Improve Outcomes

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Mar 28, 2023 58:12


Go online to PeerView.com/KZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how to apply the evidence that supports modern therapeutics in conjunction with allogeneic hematopoietic stem cell (HCT)! This "Clinical Consults" activity features an expert-led, case-centered discussion focusing on therapeutic decision-making in HCT-eligible acute myeloid leukemia (AML). Throughout, the panelists weigh in on topics such as how to incorporate targeted options into the management of HCT-eligible patients based on FLT3 or TP53 mutations, selection of appropriate postremission maintenance, and the use of novel conditioning to expand access to HCT for AML populations with unmet medical needs. Upon completion of this activity, participants should be better able to: Characterize baseline disease- and patient-related features that can inform prognosis and facilitate treatment decisions for transplant-eligible patients with AML; Integrate novel therapies into induction, consolidation, and maintenance/postremission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines; and Incorporate novel therapies into treatment plans for patients with relapsed/refractory AML, including as pretransplant conditioning or as salvage options post-transplant

PeerView Internal Medicine CME/CNE/CPE Video Podcast
James M. Foran, MD, FRCPC, Jessica K. Altman, MD - The Convergence of Innovative Therapy and AlloHCT in AML: Applying Current Evidence to Improve Outcomes

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Mar 28, 2023 58:12


Go online to PeerView.com/KZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how to apply the evidence that supports modern therapeutics in conjunction with allogeneic hematopoietic stem cell (HCT)! This "Clinical Consults" activity features an expert-led, case-centered discussion focusing on therapeutic decision-making in HCT-eligible acute myeloid leukemia (AML). Throughout, the panelists weigh in on topics such as how to incorporate targeted options into the management of HCT-eligible patients based on FLT3 or TP53 mutations, selection of appropriate postremission maintenance, and the use of novel conditioning to expand access to HCT for AML populations with unmet medical needs. Upon completion of this activity, participants should be better able to: Characterize baseline disease- and patient-related features that can inform prognosis and facilitate treatment decisions for transplant-eligible patients with AML; Integrate novel therapies into induction, consolidation, and maintenance/postremission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines; and Incorporate novel therapies into treatment plans for patients with relapsed/refractory AML, including as pretransplant conditioning or as salvage options post-transplant

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
James M. Foran, MD, FRCPC, Jessica K. Altman, MD - The Convergence of Innovative Therapy and AlloHCT in AML: Applying Current Evidence to Improve Outcomes

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 28, 2023 58:11


Go online to PeerView.com/KZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how to apply the evidence that supports modern therapeutics in conjunction with allogeneic hematopoietic stem cell (HCT)! This "Clinical Consults" activity features an expert-led, case-centered discussion focusing on therapeutic decision-making in HCT-eligible acute myeloid leukemia (AML). Throughout, the panelists weigh in on topics such as how to incorporate targeted options into the management of HCT-eligible patients based on FLT3 or TP53 mutations, selection of appropriate postremission maintenance, and the use of novel conditioning to expand access to HCT for AML populations with unmet medical needs. Upon completion of this activity, participants should be better able to: Characterize baseline disease- and patient-related features that can inform prognosis and facilitate treatment decisions for transplant-eligible patients with AML; Integrate novel therapies into induction, consolidation, and maintenance/postremission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines; and Incorporate novel therapies into treatment plans for patients with relapsed/refractory AML, including as pretransplant conditioning or as salvage options post-transplant

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
James M. Foran, MD, FRCPC, Jessica K. Altman, MD - The Convergence of Innovative Therapy and AlloHCT in AML: Applying Current Evidence to Improve Outcomes

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 28, 2023 58:11


Go online to PeerView.com/KZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how to apply the evidence that supports modern therapeutics in conjunction with allogeneic hematopoietic stem cell (HCT)! This "Clinical Consults" activity features an expert-led, case-centered discussion focusing on therapeutic decision-making in HCT-eligible acute myeloid leukemia (AML). Throughout, the panelists weigh in on topics such as how to incorporate targeted options into the management of HCT-eligible patients based on FLT3 or TP53 mutations, selection of appropriate postremission maintenance, and the use of novel conditioning to expand access to HCT for AML populations with unmet medical needs. Upon completion of this activity, participants should be better able to: Characterize baseline disease- and patient-related features that can inform prognosis and facilitate treatment decisions for transplant-eligible patients with AML; Integrate novel therapies into induction, consolidation, and maintenance/postremission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines; and Incorporate novel therapies into treatment plans for patients with relapsed/refractory AML, including as pretransplant conditioning or as salvage options post-transplant

PeerView Clinical Pharmacology CME/CNE/CPE Video
James M. Foran, MD, FRCPC, Jessica K. Altman, MD - The Convergence of Innovative Therapy and AlloHCT in AML: Applying Current Evidence to Improve Outcomes

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Mar 28, 2023 58:12


Go online to PeerView.com/KZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how to apply the evidence that supports modern therapeutics in conjunction with allogeneic hematopoietic stem cell (HCT)! This "Clinical Consults" activity features an expert-led, case-centered discussion focusing on therapeutic decision-making in HCT-eligible acute myeloid leukemia (AML). Throughout, the panelists weigh in on topics such as how to incorporate targeted options into the management of HCT-eligible patients based on FLT3 or TP53 mutations, selection of appropriate postremission maintenance, and the use of novel conditioning to expand access to HCT for AML populations with unmet medical needs. Upon completion of this activity, participants should be better able to: Characterize baseline disease- and patient-related features that can inform prognosis and facilitate treatment decisions for transplant-eligible patients with AML; Integrate novel therapies into induction, consolidation, and maintenance/postremission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines; and Incorporate novel therapies into treatment plans for patients with relapsed/refractory AML, including as pretransplant conditioning or as salvage options post-transplant

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
James M. Foran, MD, FRCPC - Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 6, 2022 53:58


Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
James M. Foran, MD, FRCPC - Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 6, 2022 53:59


Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
James M. Foran, MD, FRCPC - Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 6, 2022 53:58


Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
James M. Foran, MD, FRCPC - Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 6, 2022 53:58


Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
James M. Foran, MD, FRCPC - Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 6, 2022 53:59


Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
James M. Foran, MD, FRCPC - Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 6, 2022 53:59


Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
James M. Foran, MD, FRCPC - Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 6, 2022 53:59


Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.

PeerView Clinical Pharmacology CME/CNE/CPE Video
James M. Foran, MD, FRCPC - Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jul 6, 2022 53:58


Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
James M. Foran, MD, FRCPC - Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 6, 2022 53:59


Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
James M. Foran, MD, FRCPC - Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 6, 2022 53:58


Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.

Treating Blood Cancers
Myelodysplastic Syndromes (MDS): Caring for Low and High-Risk Patients

Treating Blood Cancers

Play Episode Listen Later Jul 22, 2020 37:25


James M. Foran, MD, FRCPC, Mayo Clinic Cancer Center, Jacksonville, FL Recorded on May 28, 2020

Blood & Cancer
Treatment approaches in AML

Blood & Cancer

Play Episode Listen Later Feb 27, 2020 32:54


A diagnosis of acute myeloid leukemia (AML) was once an emergency, requiring immediate treatment. Today, the need to start treatment is still urgent, but many patients can benefit by waiting a few days for testing to reveal a fuller picture of the disease. That’s the advice of James M. Foran, MD, of the Mayo Clinic. He joins Blood & Cancer host David H. Henry, MD, of the Pennsylvania Hospital, Philadelphia, to walk through some patient scenarios and the newest treatment options. In Clinical Correlation, Ilana Yurkiewicz, MD, of Stanford (Calif.) University, talks about what patients do and do not remember from their visits. Practice points: Rapid testing results can drive important choices in the initial treatment of AML. Adjunctive therapies may improve survival by 7%-20% in appropriate patients. Although a total work-up may take up to 2 weeks, new research suggests it is feasible to get rapid sequencing/cytogenetic testing and assign treatment within 7 days. Treatment varies: Daunorubicin and cytarabine (Vyxeos) are still central treatment strategies, but there may be survival advantages (7%-20% improvement) by adding adjunctive therapies, if indicated. A few are listed below: Liposomal formulations of daunorubicin-cytarabine (CPX351) can have survival advantages in therapy-related AML or AML with myelodysplastic syndrome (MDS)-related changes. Gemtuzumab (Mylotarg) may be indicated for core binding factor (CBF) AML. Midostaurin (Rydapt) may improve survival in patients with FMS-like tyrosine kinase (FLT) 3 Enasidenib (Idhifa) may be indicated in patients with IDH mutations. Options for elderly patients: In a recent study, CC 486 (oral azacitidine) showed a significant survival advantage and remission duration in elderly patients with AML. The drug is not yet available but could eventually be a maintenance therapy option for patients who do not go on to transplant. Azacitidine, plus or minus an IDH2 inhibitor, showed much higher remission rates in elderly patients, but did not translate into a survival advantage. AML in the outpatient setting: Many patients with AML are being increasingly managed as outpatients, which ultimately will require a different kind of support infrastructure in our hospitals and clinics. Show notes by Debika Biswal Shinohara, MD, PhD, resident in the department of internal medicine, University of Pennsylvania, Philadelphia. Dr. Henry and Dr. Yurkiewicz reported having no financial conflicts relevant to this episode. Dr. Foran reported advisory board membership with Pfizer, Jazz Pharma, and Novartis.  * * *  For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgehemonc David Henry on Twitter: @davidhenrymd Ilana Yurkiewicz on Twitter: @ilanayurkiewicz

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Alexander Perl, MD and James M. Foran, MD, FRCPC - Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Apr 8, 2019 59:03


Go online to PeerView.com/PCE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts in the management of AML illustrate the arrival of individualized care for HCT-eligible patients by profiling updated practice guidelines that support the use of novel agents across a range of clinical settings. The expert panelists also provide insights on the efficacy and safety evidence demonstrating that improved outcomes are possible when using cutting-edge targeted therapies, epigenetic modifiers, or antibodies in conjunction with transplant for different AML populations that have not traditionally benefited from standard chemotherapy, including individuals with therapeutically relevant genetic mutations, elderly patients, or those with high-risk disease. Upon completion of this activity, participants should be better able to: Describe updates to current recommendations for the use of novel therapeutics in patients with AML who are eligible for transplant, Cite evidence on the use of newer cytotoxics, targeted agents, antibodies, and epigenetic therapies as components of induction, conditioning, or maintenance therapy in transplant-eligible patients with AML, Integrate novel strategies into the management of transplant-eligible individuals with AML, both prior to and following HCT, based on disease features and patient needs.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Alexander Perl, MD and James M. Foran, MD, FRCPC - Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Apr 8, 2019 59:16


Go online to PeerView.com/PCE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts in the management of AML illustrate the arrival of individualized care for HCT-eligible patients by profiling updated practice guidelines that support the use of novel agents across a range of clinical settings. The expert panelists also provide insights on the efficacy and safety evidence demonstrating that improved outcomes are possible when using cutting-edge targeted therapies, epigenetic modifiers, or antibodies in conjunction with transplant for different AML populations that have not traditionally benefited from standard chemotherapy, including individuals with therapeutically relevant genetic mutations, elderly patients, or those with high-risk disease. Upon completion of this activity, participants should be better able to: Describe updates to current recommendations for the use of novel therapeutics in patients with AML who are eligible for transplant, Cite evidence on the use of newer cytotoxics, targeted agents, antibodies, and epigenetic therapies as components of induction, conditioning, or maintenance therapy in transplant-eligible patients with AML, Integrate novel strategies into the management of transplant-eligible individuals with AML, both prior to and following HCT, based on disease features and patient needs.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Alexander Perl, MD and James M. Foran, MD, FRCPC - Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Apr 8, 2019 59:03


Go online to PeerView.com/PCE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts in the management of AML illustrate the arrival of individualized care for HCT-eligible patients by profiling updated practice guidelines that support the use of novel agents across a range of clinical settings. The expert panelists also provide insights on the efficacy and safety evidence demonstrating that improved outcomes are possible when using cutting-edge targeted therapies, epigenetic modifiers, or antibodies in conjunction with transplant for different AML populations that have not traditionally benefited from standard chemotherapy, including individuals with therapeutically relevant genetic mutations, elderly patients, or those with high-risk disease. Upon completion of this activity, participants should be better able to: Describe updates to current recommendations for the use of novel therapeutics in patients with AML who are eligible for transplant, Cite evidence on the use of newer cytotoxics, targeted agents, antibodies, and epigenetic therapies as components of induction, conditioning, or maintenance therapy in transplant-eligible patients with AML, Integrate novel strategies into the management of transplant-eligible individuals with AML, both prior to and following HCT, based on disease features and patient needs.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Alexander Perl, MD and James M. Foran, MD, FRCPC - Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Apr 8, 2019 59:16


Go online to PeerView.com/PCE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts in the management of AML illustrate the arrival of individualized care for HCT-eligible patients by profiling updated practice guidelines that support the use of novel agents across a range of clinical settings. The expert panelists also provide insights on the efficacy and safety evidence demonstrating that improved outcomes are possible when using cutting-edge targeted therapies, epigenetic modifiers, or antibodies in conjunction with transplant for different AML populations that have not traditionally benefited from standard chemotherapy, including individuals with therapeutically relevant genetic mutations, elderly patients, or those with high-risk disease. Upon completion of this activity, participants should be better able to: Describe updates to current recommendations for the use of novel therapeutics in patients with AML who are eligible for transplant, Cite evidence on the use of newer cytotoxics, targeted agents, antibodies, and epigenetic therapies as components of induction, conditioning, or maintenance therapy in transplant-eligible patients with AML, Integrate novel strategies into the management of transplant-eligible individuals with AML, both prior to and following HCT, based on disease features and patient needs.

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Alexander Perl, MD and James M. Foran, MD, FRCPC - Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

Play Episode Listen Later Apr 8, 2019 59:03


Go online to PeerView.com/PCE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts in the management of AML illustrate the arrival of individualized care for HCT-eligible patients by profiling updated practice guidelines that support the use of novel agents across a range of clinical settings. The expert panelists also provide insights on the efficacy and safety evidence demonstrating that improved outcomes are possible when using cutting-edge targeted therapies, epigenetic modifiers, or antibodies in conjunction with transplant for different AML populations that have not traditionally benefited from standard chemotherapy, including individuals with therapeutically relevant genetic mutations, elderly patients, or those with high-risk disease. Upon completion of this activity, participants should be better able to: Describe updates to current recommendations for the use of novel therapeutics in patients with AML who are eligible for transplant, Cite evidence on the use of newer cytotoxics, targeted agents, antibodies, and epigenetic therapies as components of induction, conditioning, or maintenance therapy in transplant-eligible patients with AML, Integrate novel strategies into the management of transplant-eligible individuals with AML, both prior to and following HCT, based on disease features and patient needs.

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Alexander Perl, MD and James M. Foran, MD, FRCPC - Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

Play Episode Listen Later Apr 8, 2019 59:16


Go online to PeerView.com/PCE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts in the management of AML illustrate the arrival of individualized care for HCT-eligible patients by profiling updated practice guidelines that support the use of novel agents across a range of clinical settings. The expert panelists also provide insights on the efficacy and safety evidence demonstrating that improved outcomes are possible when using cutting-edge targeted therapies, epigenetic modifiers, or antibodies in conjunction with transplant for different AML populations that have not traditionally benefited from standard chemotherapy, including individuals with therapeutically relevant genetic mutations, elderly patients, or those with high-risk disease. Upon completion of this activity, participants should be better able to: Describe updates to current recommendations for the use of novel therapeutics in patients with AML who are eligible for transplant, Cite evidence on the use of newer cytotoxics, targeted agents, antibodies, and epigenetic therapies as components of induction, conditioning, or maintenance therapy in transplant-eligible patients with AML, Integrate novel strategies into the management of transplant-eligible individuals with AML, both prior to and following HCT, based on disease features and patient needs.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Alexander Perl, MD and James M. Foran, MD, FRCPC - Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Apr 8, 2019 59:03


Go online to PeerView.com/PCE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts in the management of AML illustrate the arrival of individualized care for HCT-eligible patients by profiling updated practice guidelines that support the use of novel agents across a range of clinical settings. The expert panelists also provide insights on the efficacy and safety evidence demonstrating that improved outcomes are possible when using cutting-edge targeted therapies, epigenetic modifiers, or antibodies in conjunction with transplant for different AML populations that have not traditionally benefited from standard chemotherapy, including individuals with therapeutically relevant genetic mutations, elderly patients, or those with high-risk disease. Upon completion of this activity, participants should be better able to: Describe updates to current recommendations for the use of novel therapeutics in patients with AML who are eligible for transplant, Cite evidence on the use of newer cytotoxics, targeted agents, antibodies, and epigenetic therapies as components of induction, conditioning, or maintenance therapy in transplant-eligible patients with AML, Integrate novel strategies into the management of transplant-eligible individuals with AML, both prior to and following HCT, based on disease features and patient needs.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Alexander Perl, MD and James M. Foran, MD, FRCPC - Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Apr 8, 2019 59:16


Go online to PeerView.com/PCE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts in the management of AML illustrate the arrival of individualized care for HCT-eligible patients by profiling updated practice guidelines that support the use of novel agents across a range of clinical settings. The expert panelists also provide insights on the efficacy and safety evidence demonstrating that improved outcomes are possible when using cutting-edge targeted therapies, epigenetic modifiers, or antibodies in conjunction with transplant for different AML populations that have not traditionally benefited from standard chemotherapy, including individuals with therapeutically relevant genetic mutations, elderly patients, or those with high-risk disease. Upon completion of this activity, participants should be better able to: Describe updates to current recommendations for the use of novel therapeutics in patients with AML who are eligible for transplant, Cite evidence on the use of newer cytotoxics, targeted agents, antibodies, and epigenetic therapies as components of induction, conditioning, or maintenance therapy in transplant-eligible patients with AML, Integrate novel strategies into the management of transplant-eligible individuals with AML, both prior to and following HCT, based on disease features and patient needs.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Alexander Perl, MD and James M. Foran, MD, FRCPC - Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Apr 8, 2019 59:03


Go online to PeerView.com/PCE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts in the management of AML illustrate the arrival of individualized care for HCT-eligible patients by profiling updated practice guidelines that support the use of novel agents across a range of clinical settings. The expert panelists also provide insights on the efficacy and safety evidence demonstrating that improved outcomes are possible when using cutting-edge targeted therapies, epigenetic modifiers, or antibodies in conjunction with transplant for different AML populations that have not traditionally benefited from standard chemotherapy, including individuals with therapeutically relevant genetic mutations, elderly patients, or those with high-risk disease. Upon completion of this activity, participants should be better able to: Describe updates to current recommendations for the use of novel therapeutics in patients with AML who are eligible for transplant, Cite evidence on the use of newer cytotoxics, targeted agents, antibodies, and epigenetic therapies as components of induction, conditioning, or maintenance therapy in transplant-eligible patients with AML, Integrate novel strategies into the management of transplant-eligible individuals with AML, both prior to and following HCT, based on disease features and patient needs.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Alexander Perl, MD and James M. Foran, MD, FRCPC - Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Apr 8, 2019 59:16


Go online to PeerView.com/PCE860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts in the management of AML illustrate the arrival of individualized care for HCT-eligible patients by profiling updated practice guidelines that support the use of novel agents across a range of clinical settings. The expert panelists also provide insights on the efficacy and safety evidence demonstrating that improved outcomes are possible when using cutting-edge targeted therapies, epigenetic modifiers, or antibodies in conjunction with transplant for different AML populations that have not traditionally benefited from standard chemotherapy, including individuals with therapeutically relevant genetic mutations, elderly patients, or those with high-risk disease. Upon completion of this activity, participants should be better able to: Describe updates to current recommendations for the use of novel therapeutics in patients with AML who are eligible for transplant, Cite evidence on the use of newer cytotoxics, targeted agents, antibodies, and epigenetic therapies as components of induction, conditioning, or maintenance therapy in transplant-eligible patients with AML, Integrate novel strategies into the management of transplant-eligible individuals with AML, both prior to and following HCT, based on disease features and patient needs.